LDL Cholesterolemia as a Novel Risk Factor for Radiographic Progression of Rheumatoid Arthritis: A Single-Center Prospective Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Park, Yune Jung ^a   Cho, Chul Soo ^a   Emery, Paul ^b,c   Kim, Wan Uk ^a  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISOLONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PROBABILITY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

EID: 84880779498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068975     Document Type: Article

References (45)

1. Struthers GR, Scott DL, Bacon PA, Walton KW, (1983) Musculoskeletal disorders in patients with hyperlipidaemia. Ann Rheum Dis 42: 519-523.
2. Li W, Han J, Qureshi AA, (2012) Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71: 1267-1272.
3. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, et al. (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71: 1273-1277.
4. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, et al. (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40: 1955-1961.
5. Jick SS, Choi H, Li L, McInnes IB, Sattar N, (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68: 546-551.
6. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, et al. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363: 2015-2021.
7. James MJ, van Reyk D, Rye KA, Dean RT, Cleland LG, et al. (1998) Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized. Lipids 33: 1115-1121.
8. Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, et al. (1993) Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 52: 677-680.
9. Park YJ, Yoo SA, Choi S, Yoo HS, Yoon HS, et al. (2013) Association of Polymorphisms Modulating Low-density Lipoprotein Cholesterol with Susceptibility, Severity, and Progression of Rheumatoid Arthritis. J Rheumatol [in press].
10. Park YJ, Yoo SA, Lee JH, Chung YJ, Cho CS, et al. (2012) The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia. Clin Exp Rheumatol 31: 180-188.
11. Yoo WH, (2004) Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 31: 1746-1753.
12. Choy E, Sattar N, (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68: 460-469.
13. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, et al. (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70: 482-487.
14. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O, (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122: 1837-1845.
15. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, et al. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117: 195-205.
16. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK, (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26: 1495-1498.
17. Tilg H, Moschen AR, (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6: 772-783.
18. Giles JT, Allison M, Bingham CO, 3rd, Scott WM, Jr., Bathon JM (2009) Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 61: 1248-1256.
19. Giles JT, van der Heijde DM, Bathon JM, (2011) Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 70: 1562-1568.
20. Park YB, Choi HK, Kim MY, Lee WK, Song J, et al. (2002) Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 113: 188-193.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
22. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
23. van der Heijde D, (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27: 261-263.
24. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, et al. (2005) Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 25: 241-245.
25. Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, et al. (2001) Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 44: 2761-2767.
26. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, et al. (2007) Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 66: 1503-1507.
27. Feldmann M, Maini RN, (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163-196.
28. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, et al. (2011) What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7: 528-536.
29. Xibille-Friedmann D, Bustos-Bahena C, Hernandez-Gongora S, Burgos-Vargas R, Montiel-Hernandez JL, (2010) Two-year follow-up of plasma leptin and other cytokines in patients with rheumatoid arthritis. Ann Rheum Dis 69: 930-931.
30. Bokarewa M, Bokarew D, Hultgren O, Tarkowski A, (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62: 952-956.
31. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, Van Zeben D, Vos K, et al. (2002) Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 47: 383-390.
32. Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, et al. (2009) Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol 28: 445-451.
33. Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, et al. (2011) Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 63: 2567-2574.
34. Rho YH, Solus J, Sokka T, Oeser A, Chung CP, et al. (2009) Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 60: 1906-1914.
35. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, et al. (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45: 1169-1196.
36. Dawes PT, Fowler PD, Jackson R, Collins M, Shadforth MF, et al. (1986) Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy. Ann Rheum Dis 45: 945-949.
37. Wilding P, Kendall MJ, Holder R, Grimes JA, Farr M, (1975) The influence of drugs and disease activity on biochemical and haematological data in rheumatoid arthritis. Clin Chim Acta 64: 185-194.
38. Robinson DR, McGuire MB, Levine L, (1975) Prostaglandins in the rheumatic diseases. Ann N Y Acad Sci 256: 318-329.
39. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP, (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63: 359-364.
40. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, et al. (2012) Obesity reduces the response rate to anti TNFalpha in rheumatoid arthritis. an approach to a personalized medicine. Arthritis Care Res (Hoboken).
41. Valente AJ, Walton KW, (1980) Studies on increased vascular permeability in the pathogenesis of lesions of connective tissue diseases: I. Experimental hyperlipidaemia and immune arthropathy. Ann Rheum Dis 39: 490-499.
42. Seven A, Guzel S, Aslan M, Hamuryudan V, (2009) Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int 29: 743-747.
43. van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, et al. (2007) Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 66: 184-188.
44. Busso N, So A, Chobaz-Peclat V, Morard C, Martinez-Soria E, et al. (2002) Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 168: 875-882.
45. Hamnvik OP, Liu X, Petrou M, Gong H, Chamberland JP, et al. (2011) Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study. Metabolism 60: 987-993.